Tg Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Tg Therapeutics Inc 's ROA in the second quarter of 2026?
Tg Therapeutics Inc achieved a return on average assets (ROA) of 33.62 % in its second quarter of 2026, this is above TGTX's average return on assets of -79.56%.
Tg Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,313 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 29 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 87, from total ROA ranking in the first quarter of 2026 at 90.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	135.05 %	134.69 %	86.15 %	76.2 %	76.55 %
Y / Y Net Income Change	-72.4 %	290.85 %	-1.26 %	9974.61 %	309.75 %
Net Income (TTM) in million	441	462	447	447	60
Return On Assets (TTM)	33.62 %	42.87 %	52.11 %	60.87 %	9.68 %
TGTX's Total Ranking	# 87	# 90	# 56	# 647	# 890
Total Assets (TTM) in million	1,640	1,529	1,063	1,021	698
Seq. Total Assets Change	7.25 %	43.79 %	4.19 %	46.3 %	7.08 %
Seq. Net Income Change	-60.66 %	-14.15 %	-94.11 %	1286.79 %	457.06 %

TGTX's 5 Years Annual ROA >> Back to TGTX Management Effectiveness >> Compare TGTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 17
Sector	# 30
Overall	# 111

Return On Assets Statistics
High	Average	Low
60.43 %	-79.56 %	-224.85 %
(Sep 30 2025)		(Mar 31 2020)

News about Tg Therapeutics Inc Return on Assets ROA

TG Therapeutics Surprises Market with Positive Net Revenue in Q4 2023, Despite Previous Losses

Investigation Reveals TG Therapeutics Positive Net Revenue in Fourth Quarter and Full Year 2023 Despite Previous Losses
TG Therapeutics, a biopharmaceutical company specializing in the development of innovative treatments, has announced preliminary net revenue figures for the fourth quarter and full year 2023. The company reported net product revenue of approximately $40 million for the fourth quarter and $89 million for the full year. These figures come as a surprise, considering TG Therapeutics had recorded a cumulative net loss of $-26 million in the 12 months leading up to the third quarter of 2023.
The revelation of TG Therapeutics positive net revenue raises questions about the company s financial performance and its ability to recover from previous losses. Furthermore, it sparks curiosity about the potential reasons behind the drastic change in revenue in such a short period.

Financial Statements
Tg Therapeutics Inc 's Assets	$ 1,640 million	TGTX's Balance sheet
Tg Therapeutics Inc 's Income	$ 8 million	Quarterly TGTX's Income Statement
TGTX's Income by Division		See TGTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	96.51 %	73.98 %	75.76 %	-50.04 %	-51.62 %
Total Assets in million	1,122	571	328	187	374
Y / Y Net Income Change	1812.41 %	84.52 %	-	-	-
Net Income in million	447	23	13	-198	-348
Annual Return On Assets	39.84 %	4.09 %	3.86 %	-106.18 %	-93.1 %

TGTX's 5 Years Annual ROA >> Back to TGTX Management Effectiveness >> Compare TGTX ROA to its Competitors

Comment on TGTX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 39.84 % compared to prior year, due to annual net income growth of 1812.41 % to $447.18 million, while value of Tg Therapeutics Inc 's overall assets grew just by 96.51 % to $1,122.39 million, compared to $1,122.39 a year before.

More Return On Assets Ratios
TGTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TGTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TGTX's Competitors
Subscribers only: Roa for Tg Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for TGTX's Customers

You may also want to know
TGTX's Roi	TGTX's Inventory Turnover Ratio	TGTX's Growth Rates	TGTX's Dividend Comparisons
	TGTX's Profitability Ratios	TGTX's Asset Turnover Ratio	TGTX's Dividend Growth
TGTX's Roe	TGTX's Valuation Ratios	TGTX's Financial Strength Ratios	TGTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %

Date modified: 2026-09-09T22:26:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.